120 related articles for article (PubMed ID: 24647344)
1. NICE uses wrong comparator to assess cost effectiveness of new drugs, report says.
Hawkes N
BMJ; 2014 Mar; 348():g2134. PubMed ID: 24647344
[No Abstract] [Full Text] [Related]
2. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
3. The Office of Fair Trading report: a prescription for value-based drug pricing.
Minhas R; Moon JC
J R Soc Med; 2007 May; 100(5):216-8. PubMed ID: 17470928
[No Abstract] [Full Text] [Related]
4. Government pushes ahead with plan for cheaper drugs deal for NHS.
Timmins N
BMJ; 2007 Aug; 335(7614):273. PubMed ID: 17690350
[No Abstract] [Full Text] [Related]
5. Data briefing. The NICE threshold.
Appleby J
Health Serv J; 2007 Sep; 117(6074):21. PubMed ID: 17970386
[No Abstract] [Full Text] [Related]
6. NICE is too generous in approving drugs, analysis says.
Hawkes N
BMJ; 2015 Feb; 350():h955. PubMed ID: 25698770
[No Abstract] [Full Text] [Related]
7. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
8. US politicians want federal funding to discover cost effectiveness of new drugs.
Moynihan R
BMJ; 2003 Sep; 327(7416):642. PubMed ID: 14500428
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness data on biologics needed.
Sheridan C; Katsnelson A
Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
[No Abstract] [Full Text] [Related]
10. Can NICE be nicer? In a world of budget constraints there are no easy solutions.
Drummond M; Sorenson C
Value Health; 2009; 12(5):634-6. PubMed ID: 19402855
[TBL] [Abstract][Full Text] [Related]
11. How NICE may be outflanked.
Ferner RE; McDowell SE
BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
[No Abstract] [Full Text] [Related]
12. Health technology assessment in the United Kingdom.
Akehurst R
Value Health; 2010 Jun; 13 Suppl 1():S4-5. PubMed ID: 20618794
[No Abstract] [Full Text] [Related]
13. Priced out of the UK market.
Moran N
Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
[No Abstract] [Full Text] [Related]
14. Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices-A European Perspective.
Messori A; Trippoli S
Ther Innov Regul Sci; 2018 Nov; 52(6):755-756. PubMed ID: 29714590
[No Abstract] [Full Text] [Related]
15. How cheap are Canada's drugs really?
Hollis A
J Pharm Pharm Sci; 2004 Jun; 7(2):215-6. PubMed ID: 15367378
[TBL] [Abstract][Full Text] [Related]
16. Should NICE's threshold range for cost per QALY be raised? No.
Raftery J
BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
[No Abstract] [Full Text] [Related]
17. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
18. Should NICE's threshold range for cost per QALY be raised? Yes.
Towse A
BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
[No Abstract] [Full Text] [Related]
19. Should cost-effectiveness take the blame?
McGregor M
CMAJ; 2003 Jun; 168(12):1528; author reply 1528-9. PubMed ID: 12796326
[No Abstract] [Full Text] [Related]
20. The economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
